Citizens JMP raised the firm’s price target on MBX Biosciences (MBX) to $61 from $38 and keeps an Outperform rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX:
- Pfizer to acquire Metsera, Oracle names new CEOs: Morning Buzz
- MBX Biosciences price target raised to $80 from $38 at Oppenheimer
- MBX Biosciences Stock Rockets on Clinical Trial Update
- Morning Movers: Metsera surges, Pfizer gains after acquisition pact
- Video: Metsera jumps after Pfizer strikes deal for obesity drugmaker